Eindhoven-based Sirius Medical has announced securing €10M in scale-up funding, coinciding with World Cancer Day. The medical device company, known for its Pintuition technology, aims to address critical challenges in cancer treatment through innovation. The funding aims to expand its market reach, enhance technological capabilities, and improve its product offerings for tumour localisation. Sirius Medical has gained recognition globally for its precise surgical navigation solutions, which are widely adopted by surgeons, particularly in breast-conserving surgeries.
Who participated in the investment round?
This funding round saw participation from Invest-NL and Nextgen Ventures, alongside contributors such as the De Groot Family Office, and existing investors like Brabant Development Agency (BOM), Holland Capital, Curie Capital, and Team Holmium. The announcement highlights Invest-NL’s role as an impact investor supporting sustainable and innovative healthcare solutions. According to Karin Steffens, senior investment manager at Invest-NL:
“Sirius Medical’s mission to develop sustainable technology solutions while maintaining balance within the healthcare system closely aligns with our mission to accelerate the healthcare transition. We are excited to back a company making such a meaningful difference for women with breast cancer.”
How will the funds be utilized?
Sirius Medical plans to channel the investment toward enhancing its Sirius Pintuition system and GPSDetect software platform, focusing on improving usability and expanding its applications. Additionally, the company intends to strengthen its sales infrastructure and venture into new markets. CEO Bram Schermers commented:
“Announcing this funding milestone on World Cancer Day underscores the urgency of our mission to improve cancer care globally. This funding round is a testament to the talent of the Sirius Medical team and the Pintuition technology that we have developed.”
When compared to the €12M Series B funding it raised two years ago, this recent investment further solidifies the company’s growth trajectory. The previous funding helped Sirius Medical expand its reach across Western Europe and the US, allowing its technology to be integrated into over 250 centres and enabling more than 35,000 procedures globally. Both the CE-mark and FDA-clearance of the Pintuition platform have facilitated its market acceptance.
Sirius Medical’s Pintuition technology is gaining traction due to its ability to guide surgeons with real-time distance and directional data for tumour localisation. This wire-free system offers advanced localisation for breast-conserving surgery and has been implemented successfully in Western Europe and the US. As the technology continues to be adopted, experts see significant growth potential, particularly in untapped regions. Roel Dekkers, investment manager at Nextgen Ventures, remarked:
“The Sirius Medical leadership team has shown exceptional expertise and adaptability. The company is well positioned for expansion, and we see a tremendous opportunity for growth in untapped markets.”
With the latest funding, the company is not only aiming for technological advancements but also a broader global impact in cancer treatment. These developments highlight the importance of innovation in healthcare, particularly in addressing challenging cancer treatments through precision tools.
For readers, it is noteworthy that while Sirius Medical’s efforts are focusing primarily on usability and market expansion, the larger picture underscores the critical need for cost-effective, tech-driven solutions in healthcare. With the global impact of cancer growing, investments in technologies like Pintuition reflect a shift toward precision-based treatments, which could potentially reduce healthcare costs over time. However, as with any technology, sustained success will depend on its ability to adapt to diverse medical systems and its affordability in emerging markets.
